Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-Free DNA Methylation

Researchers developed a targeted DNA methylation assay to detect castration-resistant neuroendocrine prostate cancer (CRPC-NE) using plasma cell-free DNA, which quantified tumor content and provided a phenotype evidence score that captured diverse CRPC phenotypes, leveraging regions to inform transcriptional state.